The media refute why these cancer patients want to go to the United States: the fallacy is obvious.

category:Internet click:436
 The media refute why these cancer patients want to go to the United States: the fallacy is obvious.


Newspaper reporter Zhang Jiaxing

The news of CCTV host Li Yongs death from cancer came from the United States. Some people turned up an old article published in August 2016, Why are these cancer patients going to the United States? This article attempts to give an unrealistic explanation to the minority groups choice of 3,000 people per year going to the United States for cancer treatment.

Through consulting the industry experts, the science and Technology Daily reporter summarized several obvious fallacies of the report.

Comparing foreign clinical trials with domestic clinical treatments

It uses an unforgettable analogy: its like the United States is using the iPhone 6, and were still using the iPhone 3.

Compared to the iPhone 6, clinical trials were conducted in the United States, while compared to the iPhone 3, clinical treatments were conducted in China.

Failing to get a new drug certificate is the most obvious difference between clinical treatment and clinical trials. If we must use the metaphor in the text, we can only say that the US is using the iPhone6 prototype.

A drug from embryonic form to market is a long process. This process can be roughly divided into pre clinical and clinical trials. The former includes compounds of drug precursors, pharmacokinetics and pharmacodynamics analysis, and effective safety tests at cellular and animal levels. After the scientific design and strict implementation of the clinical trials, they are submitted to the drug examination department for approval. After obtaining the new drug certificate, they can be listed for clinical treatment.

But for the special field of new drugs, only a small number of prototype can really go public. Fan Daiming, an academician of the Chinese Academy of Engineering, cited a group of cases in which 101 major discoveries were published in papers covering the most authoritative CNS (Cells, Nature and Science) on potential drug targets, only one of which had clinical value 20 years later.

Avoiding the high risk of clinical trials

The greatest correlation with patients themselves, and the greatest difference between clinical trials and clinical treatment, lies in the different risks.

In August 30, 2017, the first CAR-T therapy was approved in the United States. However, in April of that year, in another companys clinical trial of CAR-T drugs, a patient with refractory non-Hodgkins lymphoma (NHL) died of brain edema.

The clinical trials of innovative drugs are highly risky. Zhao Liyan, the ethics committee of Peking University Medical Department, said that although safety and effectiveness had been tested in vitro on cells and model animals, there were differences between animals and humans, so there was a great risk in humans.

In this paper, only cases with positive signs were recorded in clinical trials, but the great risks of clinical trials themselves were not mentioned.

Deliberately belittle the current medical level in China

The article Why do these cancer patients go to the United States deliberately depreciates the current medical level in China. For example, the article mentions that clinical medicine in the United States is moving toward precision medicine. A patient is often treated by doctors from multiple disciplines. In fact, in many hospitals in China, multi-disciplinary consultation has become a routine system for the diagnosis of difficult and complicated diseases, even through telemedicine and other means of cross-hospital expert consultation.

In addition, Chinas medical resources are recognized by the world as an advantage. The clinical medical technology of our country is advanced in the world, and the clinicians of the first-class hospitals in our country also have more abundant clinical experience. Lu Lin, academician of the Chinese Academy of Sciences and professor of Peking University Medical Department, said that many patients who went abroad to see a doctor might not be able to get the best treatment.

The description of Chinas GCP platform is partial.

The description of Chinas GCP platform is also inconsistent with reality. The GCP platform is the demonstration platform for the management of clinical trials of drugs. Relevant data show that China promulgated the Standards for Quality Management of Drug Clinical Trials in 2003, carried out special inspection in 2006, flight inspection and registration verification, and then improved the standard of identification and review. The national Eleventh Five-Year and Twelfth Five-Year major new drug creation special plans also gave strong support.

The comments of the respondents may reflect the adverse events of some institutions and some stages, but they can not fully reflect the real scientific research level and clinical trial level of the GCP platform in China.

According to the relevant data of national major new drug creation projects, 9 GCP platforms, such as Cancer Hospital, Tiantan Hospital and West China Hospital, were supported to carry out 2063 clinical trials from January 2015 to August 2017, and 708 clinical trials were completed. Some platforms actively implement such measures as independence of clinical trial departments, full-time researchers, normalization of rotation system and standardization of performance appraisal to stimulate staff enthusiasm and improve the quantity and quality of clinical research. In addition, the article still has many problems that can not withstand detailed investigation. For example, it is very unscientific to judge the effectiveness, safety and stability of a therapy from the time of its emergence. For example, it is worth discussing whether CRO (Medical Research and Development Contract Outsourcing Services) companys new combination mode of participating in clinical trials is more in line with Chinas national conditions. It can not be regarded as a backward mode simply because it is different from the developed countries in the United States. Source: ScienceDaily daily, editor of China Science and Technology Net: Wang Fengzhi _NT2541

According to the relevant data of national major new drug creation projects, 9 GCP platforms, such as Cancer Hospital, Tiantan Hospital and West China Hospital, were supported to carry out 2063 clinical trials from January 2015 to August 2017, and 708 clinical trials were completed.

Some platforms actively implement such measures as independence of clinical trial departments, full-time researchers, normalization of rotation system and standardization of performance appraisal to stimulate staff enthusiasm and improve the quantity and quality of clinical research.

In addition, the article still has many problems that can not withstand detailed investigation. For example, it is very unscientific to judge the effectiveness, safety and stability of a therapy from the time of its emergence. For example, it is worth discussing whether CRO (Medical Research and Development Contract Outsourcing Services) companys new combination mode of participating in clinical trials is more in line with Chinas national conditions. It can not be regarded as a backward mode simply because it is different from the developed countries in the United States.